Saturday, 08 August 2020


Rush Gene Service helps develop H7N9 vaccine

09 July 2013 | News | By BioSpectrum Bureau

GenScript's Rush Gene Service helps develop H7N9 vaccine

On May 10, 2013, Novavax announced that its vaccine candidate was developed and entered into pre-clinical trials in only 28 days

On May 10, 2013, Novavax announced that its vaccine candidate was developed and entered into pre-clinical trials in only 28 days

Singapore: GenScript, global provider of synthetic genes, has collaborated with NASDAQ listed Novavax in developing an avian influenza A/H7N9 vaccine candidate, by synthesizing three constructs containing genes that encode for key vaccine proteins.

On May 10, 2013, Novavax announced that its vaccine candidate was developed and entered into pre-clinical trials in only 28 days, less than six weeks after initial reports of H7N9 infections on April 1.

The manufacture of the constructs used in Novavax's H7N9 vaccine candidate is powered by GenScript's Rush Gene Service, which synthesizes gene sequences in as few as four days. Normally, it takes researchers, using traditional laboratory methods, two weeks or more to assemble constructs like those used to produce an H7N9 vaccine. However, as demonstrated by the rapid development of Novavax' vaccine candidate, the combination of gene optimization, rush gene synthesis and custom cloning, facilitated by GenScript's one-stop service platform, can drastically reduce assembly time, accelerating research and development.

"Our mission is to save lives by helping scientists accelerate their research. In this case, our Rush Gene Services are the perfect example of our commitment to our mission," said Dr Frank Zhang, CEO, GenScript.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls